Reversion the multidrug resistance of human breast carcinoma cells by RNA interference targeting HIF-1 alpha gene / 中华病理学杂志
Zhonghua Bing Li Xue Za Zhi
; (12): 357-360, 2006.
Article
em Zh
| WPRIM
| ID: wpr-277399
Biblioteca responsável:
WPRO
ABSTRACT
<p><b>OBJECTIVE</b>To reverse the multidrug resistant (MDR) phenotype of human breast carcinoma cells by small hairpin RNA (shRNA) technique targeting hypoxia-inducible factor (HIF)-1alpha gene.</p><p><b>METHODS</b>Small hairpin RNA (shRNA) eukaryotic expression vector targeting HIF-1alpha gene, named pSilencer-HIF, was constructed and transfected into MCF-7/ADR human breast cancer cells by liposome technique. Tumor cell livability (TCL) and Rhodamine 123 efflux assay were used to monitor the biological changes of the transfected cells. The mRNA and protein expression of HIF-1alpha and mdr-1 were investigated by RT-PCR and Western blot.</p><p><b>RESULTS</b>The successful construction of pSilencer-HIF plasmid was confirmed by DNA sequencing. HIF-1alpha mRNA and protein levels were significantly decreased in MCF-7/ADR cells after the transfection and there was a direct correlation between HIF-1alpha and mdr-1 expression. By comparing the cells transfected with control vector and the MCF-7/ADR cells transfected with pSilencer-HIF, a reduced TCL from 76% to 43%, and an increased Rhodamine 123 fluorescence intensity from 22.0% to 86.6% were observed.</p><p><b>CONCLUSIONS</b>pSilencer-HIF-1alpha has been successfully constructed. The inhibition of HIF-1alpha expression through shRNA technique can significantly reverse the multidrug resistance phenotype of MCF-7/ADR cells.</p>
Texto completo:
1
Base de dados:
WPRIM
Assunto principal:
Patologia
/
Farmacologia
/
Fisiologia
/
Neoplasias da Mama
/
Resistência a Múltiplos Medicamentos
/
Resistencia a Medicamentos Antineoplásicos
/
RNA Interferente Pequeno
/
Interferência de RNA
/
Linhagem Celular Tumoral
/
Subunidade alfa do Fator 1 Induzível por Hipóxia
Limite:
Humans
Idioma:
Zh
Ano de publicação:
2006
Tipo de documento:
Article